medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2019, Número 2

<< Anterior Siguiente >>

Acta Pediatr Mex 2019; 40 (2)


Sobrecrecimiento bacteriano en el intestino delgado: una causa de dolor abdominal crónico en niños

Avelar-Rodríguez, David; Toro-Monjaraz, Erick Manuel; Ramírez-Mayans, Jaime Alfonso

Idioma: Español
Referencias bibliográficas: 18
Paginas: 93-98
Archivo PDF: 410.60 Kb.


FRAGMENTO

ANTECEDENTES

El sobrecrecimiento bacteriano en el intestino delgado (SBID) es causa de dolor abdominal crónico, diarrea, distensión abdominal y flatulencias en la población pediátrica. El uso de inhibidores de bomba de protones, algunas anomalías anatómicas y alteraciones en la motilidad gastrointestinal son factores de riesgo de SBID. El diagnóstico se establece con base en la prueba de hidrogeniones y de metano, o por medio del cultivo del aspirado duodenal/yeyunal. El tratamiento consiste en: rifaximina, dieta con restricción de oligosacáridos, disacáridos, monosacáridos y polioles fermentables (FODMAPs), y probióticos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sieczkowska A, et al. Small bowel bacterial overgrowth in children. J Pediatr Gastroenterol Nutr. 2016;62(2):196-207. doi: 10.1097/MPG.0000000000000920

  2. Bohm M, et al. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28(3):289- 99. doi: 10.1177/0884533613485882

  3. Lo WK, et al. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90. doi: 10.1016/j. cgh.2012.12.011.

  4. Cares K, et al. Short article: Risk of small intestinal bacterial overgrowth with chronic use of proton pump inhibitors in children. Eur J Gastroenterol Hepatol. 2017;29(4):396-399. doi: 10.1097/MEG.0000000000000815

  5. Su T, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018 Jan;53(1):27-36. doi: 10.1007/s00535-017-1371-9

  6. Collins BS, et al. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci. 2010;55(1):124-30. DOI: 10.1007/ s10620-009-1026-7 ·

  7. Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009 Sep;155(3):416-20. doi: 10.1016/j.jpeds.2009.03.033.

  8. Siniewicz-Luzeńczyk K, et al. Small intestinal bacterial overgrowth syndrome in children. Prz Gastroenterol. 2015;10(1):28-32. doi: 10.5114/pg.2014.47494

  9. Toro Monjaraz EM, et al. Blastocystis hominis and chronic abdominal pain in children: Is there an association between them? J Trop Pediatr. 2018;64(4):279-83. doi: 10.1093/ tropej/fmx060.

  10. Hyams JS, et al. Functional Disorders: Children and Adolescents. Gastroenterology. 2016 Feb 15. doi: 10.1053/j. gastro.2016.02.015.

  11. Gasbarrini A, et al. 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29 Suppl 1:1-49.

  12. Rezaie A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-84. doi: 10.1038/ajg.2017.46.

  13. Scarpellini E, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013;17(10):1314-20.

  14. Pistiki A, et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43(3):236-41. doi: 10.1016/j. ijantimicag.2013.12.008.

  15. Soldi S, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309-25. doi: 10.2147/CEG.S89999.

  16. Chumpitazi BP, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42(4):418-27. doi: 10.1111/apt.13286.

  17. Iacovou M. Adapting the low FODMAP diet to special populations: infants and children. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:43-45. doi: 10.1111/jgh.13696.

  18. Zhong C, et al. Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. J Clin Gastroenterol. 2017 Apr;51(4):300-11. https://doi.org/10.1097/ MCG.0000000000000814




2020     |     www.medigraphic.com